Alex Piot
banner
alexpiot.bsky.social
Alex Piot
@alexpiot.bsky.social
PhD student in Mental Health Science - UCL | Wellcome Trust
Director of Research - Centre for Evidence Based Drug Policy
Research Fellow - London School of Hygiene & Tropical Medicine
@charlotte2153.bsky.social speaking last night on record high drug-related deaths in the UK:

“[The Home Office's stance] is ideological, not evidence-based, which is why I believe the Home Office is fundamentally incapable of dealing with drug deaths and drug harm in our communities.”
November 6, 2025 at 9:38 AM
Great to see our commentary on stimulant use and nutrition hit the cover of Drink and Drug News magazine this month. Nutrition is often overlooked but crucial issue in harm reduction, time to bring it to the table ! viewer.joomag.com/ddn-october2...
DDN_October25 DDN October 2025
We have thought-provoking contributions on wellbeing in this issue – mental and physical – including our cover story (p6) in which the team demonstrate that addressing nutritional deficiency should be...
viewer.joomag.com
October 6, 2025 at 4:35 PM
Reposted by Alex Piot
The landscape of ketamine use disorder: Patient experiences and perspectives on current treatment options buff.ly/HXPQOvF @bexharding.bsky.social
May 8, 2025 at 2:01 PM
Our Op-ed on the UK’s drug death crisis, following last week’s Westminster Hall debate we helped secure. Drug-related deaths are a health issue—and should be governed by DHSC. The MDA in its current form is outdated and counterproductive.
parliamentnews.co.uk/the-uks-drug...
April 2, 2025 at 8:11 AM
Reposted by Alex Piot
New @ukparliament.parliament.uk report just released.

Our Directors of Research @alexpiot.bsky.social & Psychedelic Policy & Regulation Timmy Davis were pleased to contribute, alongside @profdavidnutt.bsky.social, @profjoneill.bsky.social and others.

post.parliament.uk/research-bri...
Psychedelic-assisted therapy for mental health: Policy considerations
Psychedelic-assisted therapy for mental health conditions is being researched in clinical trials. There are associated benefits, risks and policy considerations.
post.parliament.uk
February 18, 2025 at 2:14 PM
Reposted by Alex Piot
The #drugpolicyratchet looks set for another turn, even though the ACMD has repeatedly found no evidence that changing the class of a drug has any effect on levels of use. www.theguardian.com/society/2025... #ketamine
Home Office may reclassify ketamine in response to record levels of use
Illegal use in UK seems to reflect growth of unregulated market in US, where its high-profile users include Elon Musk
www.theguardian.com
January 8, 2025 at 6:50 AM
Reposted by Alex Piot
Powerful closing #EHRC2024 plenary. Now the time for "strong language" to achieve, maintain & build #harmreduction with/for our communities. "No more hiding behind rhetoric of 'target' & 'vulnerable' populations". "Zero tolerance on poverty, zero tolerance on inequality, zero tolerance on stigma!"
December 4, 2024 at 1:09 PM
A Private Member’s Bill proposing changes to how Schedule 2 drugs are amended is set for its second reading this Friday, with the full text now available. This could have significant implications—here’s why it matters… 👇

publications.parliament.uk/pa/bills/cbi...
publications.parliament.uk
December 3, 2024 at 11:47 AM
Looking forward to #SaferLives24 today !
November 26, 2024 at 10:17 AM